| Monoclonal antibody | |
|---|---|
| Type | Whole antibody | 
| Source | Chimeric | 
| Target | HER1 | 
| Clinical data | |
| ATC code | 
 | 
| Identifiers | |
| CAS Number | |
| ChemSpider | 
 | 
| UNII | |
| KEGG | |
Modotuximab (INN; formerly zatuximab [1] ) is a chimeric monoclonal antibody designed for the treatment of cancer. [2] It acts as an immunomodulator and binds to HER1. [3]